Related Experiment Video

Updated: Aug 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Effect of anti-inflammatory drugs on lipase in vitro

H Zwarenstein, N Sapeika, J H Holmes

    Research Communications in Chemical Pathology and Pharmacology
    |March 1, 1976
    PubMed

    Insights

    Mefenamic acid and flufenamic acid significantly inhibit lipase activity, impacting fat breakdown. Other nonsteroidal anti-inflammatory drugs showed minimal effects on this process.

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Enzymology

    Background:

    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation management.
    • Understanding the biochemical mechanisms of NSAIDs beyond their anti-inflammatory action is crucial.
    • Lipolysis, the breakdown of fats, is a key metabolic process potentially influenced by various compounds.

    Purpose of the Study:

    • To investigate the effect of mefenamic acid and related compounds on lipolysis.
    • To determine the inhibitory potential of specific NSAIDs on pancreatic lipase activity.

    Main Methods:

    • Assay of mouse pancreas lipase activity.
    • Utilized dilauric (didodecanoic) acid ester of fluorescein as a substrate.
    • Quantified the inhibitory effects of various NSAIDs, including mefenamic acid, flufenamic acid, ibuprofen, fenoprofen calcium, phenylbutazone, oxyphenbutazone, and alclofenac.

    Main Results:

    • Mefenamic acid demonstrated a significant inhibitory effect on lipolysis.
    • Flufenamic acid exhibited a lesser, but notable, inhibitory effect on lipase activity.
    • Ibuprofen, fenoprofen calcium, phenylbutazone, oxyphenbutazone, and alclofenac showed comparatively minimal inhibition of lipolysis.

    Conclusions:

    • Mefenamic acid and flufenamic acid possess significant lipase inhibitory properties.
    • These findings suggest a specific biochemical interaction of certain NSAIDs with lipolytic enzymes.
    • Further research may explore the therapeutic implications of this lipase inhibition.

    More Related Videos

    Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation10:35

    Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

    Published on: December 26, 2017

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    Related Concept Videos

    Lipid Digestion01:06

    Lipid Digestion

    Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...